Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 658.62M P/E - EPS this Y -10.00% Ern Qtrly Grth -
Income -212.22M Forward P/E -2.74 EPS next Y -10.30% 50D Avg Chg -15.00%
Sales 9.56M PEG - EPS past 5Y - 200D Avg Chg -41.00%
Dividend N/A Price/Book 1.18 EPS next 5Y - 52W High Chg -64.00%
Recommedations 1.70 Quick Ratio 7.49 Shares Outstanding 79.72M 52W Low Chg 5.00%
Insider Own 6.41% ROA -23.24% Shares Float 67.97M Beta 0.77
Inst Own 85.69% ROE -39.34% Shares Shorted/Prior 10.66M/8.62M Price 9.30
Gross Margin - Profit Margin - Avg. Volume 1,032,227 Target Price 46.71
Oper. Margin -3,043.46% Earnings Date May 7 Volume 592,968 Change -2.31%
About Avidity Biosciences, Inc.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc. News
04/22/24 Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/24 Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares
03/27/24 Avidity Biosciences to Participate in Upcoming Investor Conferences
03/15/24 Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)
03/04/24 Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy
03/04/24 Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
03/01/24 Avidity Biosciences Full Year 2023 Earnings: Misses Expectations
02/29/24 Avidity Biosciences Honors Rare Disease Day®
02/29/24 Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
05:20 PM Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
04:40 PM Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress
04:05 PM Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
02/26/24 3 Highly Rated Biotech Stocks to Buy for 300% Gains
02/20/24 Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
02/15/24 Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
02/07/24 Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
01/29/24 Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
01/05/24 Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
12/13/23 Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy
12/01/23 The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
RNA Chatroom

User Image WallStreetBuyDip Posted - 2 days ago

Here's the result for Small + Mid cap stocks. Do you see why I only buy when H% is low? I have timestamps + buy fills for everything. The result speaks for itself. Will also trade $RNA like I did for other small and mid cap stocks.

User Image peabody86 Posted - 2 days ago

$RNA don't let this current action fool you...catalysts coming this qtr and the major catalyst imo...when company releases 5mg cohort data from the ongoing Explore44 study treating patients with DMD amendable to exon44 2nd half 2024...I just keep adding small lots every week ...will be big payoff eoy!

User Image upsidetrader Posted - 4 days ago

If $XBI can turn here and stick, I love this one...$RNA couldn't pull chart

User Image dixiebull Posted - 4 days ago

$RNA ran to 26 and pulled back to 25, so we will see if that can hold for 26.50 and 28 with volume $HWH nice day trade early for us, breaking 2 foor 2.32. I don't think it's over, break of 1.50 can take it back to 2 and 2.35 $CVNA ran to 77.50 and holding vwap well, if the market is strong it can go for 78 and 80 $ALAB goes with the market and if 72.50 holds to break 73 it can get 75 $HCP gapped up after halting then ran to 31.31. Watch for 30 break to take it to 32.50 and 33 to 35

User Image enz12 Posted - 4 days ago

$RNA

User Image insiderbuyingselling Posted - 5 days ago

$RNA new insider selling: 5000 shares. http://insiderbuyingselling.com/?t=RNA

User Image Stock_Titan Posted - 5 days ago

$RNA Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/RNA/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-eg3eqc4zkxfx.html

User Image AdiDasRom Posted - 6 days ago

$RNA

User Image enz12 Posted - 6 days ago

$RNA bo price 60 minimum

User Image enz12 Posted - 1 week ago

$RNA quietly adding here

User Image peabody86 Posted - 1 week ago

$RNA expecting 30's in May...

User Image peabody86 Posted - 2 weeks ago

$RNA prelim data for the fortitude trial is due this qtr I believe...explore44 study 2nd half of this year...not familiar, but is it possible to start hitting the 2.3B milestone payments in 2024? My portfolio % of RNA is rising weekly...hoping I am judging this one right...glta

User Image enz12 Posted - 2 weeks ago

$RNA

User Image AIALuckyDog Posted - 2 weeks ago

$RNA 💯

User Image enz12 Posted - 3 weeks ago

$RNA bo

User Image bachsong Posted - 3 weeks ago

$RNA disconcerting that NO bump from Conference presentation ... no new buyers... watch out and read Peabody's message... Predict that Pricing of new shares will be $20-$22 Low volume = conference buyers waiting for new Placement of 24MM shares to be sold... That pricing will be key to continuing momo

User Image bachsong Posted - 3 weeks ago

$RNA watchout short term...pricing of new stock (25%) dilution could bring SP down to $20... IMO be patient

User Image peabody86 Posted - 3 weeks ago

$RNA I don't really like today's action...todays action hadn't happened to this degree since january...there's also a nice gap down in the 16 area...low today was 21.56...RSI cooled off all the way to the 50's...in one day,lol...if this trades tm like today...might hit that gap...yikes...

User Image enz12 Posted - 3 weeks ago

$RNA no buyout , 85 eoy

User Image Bromberger Posted - 3 weeks ago

$RNA

User Image NYG4ever Posted - 3 weeks ago

$RNA was overcooked on the RSI as well so not mad at that either...better to retrace hit the 20 MA and consolidate for that move above $27

User Image iui33 Posted - 3 weeks ago

$RNA big chunk of shares changing hands at pre-arranged price. B/o in the near horizon

User Image _www_larval_com_ Posted - 3 weeks ago

$RNA has stumbled -4% lower to -13% (~1Mv) a moment ago, 04/19 options, follow for more volatility.

User Image NYG4ever Posted - 3 weeks ago

$RNA nice dump today - its ok since I'm still up 222% since November. Huge opportunity to add on the pullbacks.

User Image iui33 Posted - 3 weeks ago

$RNA load up

User Image enz12 Posted - 3 weeks ago

$RNA bo in progress

User Image AdiDasRom Posted - 3 weeks ago

$RNA

User Image insiderbuyingselling Posted - 3 weeks ago

$RNA new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=RNA

User Image Bugseason Posted - 3 weeks ago

$RNA wow exciting science . Love the presentation my estimates for year end may be on the low side .

User Image xxxWFOxxx Posted - 3 weeks ago

$RNA AM I UNDERSTANDING THIS RIGHT? DID AN INVESTOR INVEST 432 MILLION? ON OR AROUND MARCH 4TH.

Analyst Ratings
Needham Buy Apr 11, 24
Cantor Fitzgerald Overweight Mar 14, 24
Chardan Capital Buy Mar 5, 24
Needham Buy Mar 4, 24
Needham Buy Feb 29, 24
Chardan Capital Buy Feb 29, 24
Wells Fargo Overweight Jan 3, 24
Needham Buy Nov 29, 23
Credit Suisse Outperform Aug 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LEVIN ARTHUR A Director Director Jan 22 Sell 10.13 1,859 18,832 17,471 01/23/24
Boyce Sarah President and CEO President and CEO Jan 20 Sell 10.13 5,092 51,582 44,008 01/23/24
Flanagan W. Michael CSTO CSTO Jan 20 Sell 10.13 4,129 41,827 35,871 01/23/24
McCarthy Teresa Chief Human Resource.. Chief Human Resources Officer Jan 20 Sell 10.13 2,065 20,918 17,035 01/23/24
MacLean Michael F Chief Financial Offi.. Chief Financial Officer Jan 20 Sell 10.13 1,616 16,370 16,884 01/23/24
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Feb 14 Sell 23.93 10,000 239,300 19,330 02/15/23
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Feb 14 Option 1.24 10,000 12,400 29,330 02/15/23
Boyce Sarah President and CEO President and CEO Feb 01 Sell 24.3 50,000 1,215,000 53,352 02/03/23
Boyce Sarah President and CEO President and CEO Feb 01 Option 1.24 50,000 62,000 56,573 02/03/23
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Jan 12 Sell 22 10,000 220,000 1,330 01/17/23
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Jan 12 Option 1.24 10,000 12,400 11,330 01/17/23
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Dec 29 Sell 22.01 40,000 880,400 1,330 01/03/23
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Dec 29 Option 1.24 40,000 49,600 41,330 01/03/23
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Aug 12 Option 0.89 80,000 71,200 4,829 08/31/22
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Aug 12 Sell 22.07 80,000 1,765,600 1,330 08/31/22
Boyce Sarah President and CEO President and CEO Aug 24 Option 1.24 49,900 61,876 14,855 08/26/22
Boyce Sarah President and CEO President and CEO Aug 24 Sell 22.93 49,900 1,144,207 08/26/22
Boyce Sarah President and CEO President and CEO Aug 15 Option 1.24 100 124 100 08/17/22
Boyce Sarah President and CEO President and CEO Aug 15 Sell 22.47 100 2,247 08/17/22
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Jun 28 Option 1 20,200 20,200 21,430 06/28/21
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Jun 22 Option 1.24 200 248 1,530 06/22/21
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Jun 22 Sell 27.75 200 5,550 1,330 06/22/21
LEVIN ARTHUR A Chief Scientific Off.. Chief Scientific Officer Jun 16 Sell 25.97 37,022 961,461 06/16/21